GO
Loading...

Takeover Bids

More

  • Jared Bernstein, senior fellow at The Center on Budget and Policy Priorities, and Rep. Todd Young, R-Ind., discusses how America's broken corporate tax code can cause companies, like Pfizer, to incorporate outside the U.S.

  • NEW YORK, April 28- Shares of AstraZeneca surged on Monday after a takeover offer, lifting global equity markets on speculation of further corporate deal-making, while crude oil prices fell on increased U.S. sanctions against Russia over the Ukraine crisis.

  • Pfizer, AstraZeneca about drug pipeline: Pro     Monday, 28 Apr 2014 | 11:23 AM ET

    Discussing Pfizer's push for a $100 billion deal for AstraZeneca, with Seamus Fernandez Leerink Partners managing director.

  • Pfizer is working on its next move in a potential $100 billion battle for AstraZeneca after having two bids rejected. CNBC's Meg Tirrell reports buying AstraZeneca would boost Pfizer's cancer drug pipeline.

  • STOCKHOLM, April 28- Swedish drugmaker Meda rejected an improved takeover offer from U.S. generics firm Mylan which one person familiar with the matter said valued Meda at around $9 billion including debt, driving its shares sharply back down.

  • AstraZeneca not a great company: Cramer     Monday, 28 Apr 2014 | 9:01 AM ET

    The "Squawk on the Street" team weigh in on Pfizer's bid to takeover European drug maker AstraZeneca.

  • *Pfizer works on next move in takeover bid for Astrazeneca. *U.S. drugmaker Pfizer Inc is working on its next move in a potential $100 billion bid to take over Britain's AstraZeneca Plc after having two bids rejected.

  • UPDATE 1-Meda board rejects new Mylan offer Monday, 28 Apr 2014 | 2:50 AM ET

    STOCKHOLM, April 28- Swedish drugmaker Meda has rejected an improved takeover offer from U.S. generics firm Mylan, saying it was confident in its future as an independent company and its biggest shareholder did not support the bid.

  • PARIS/ NEW YORK, April 24- Alstom said on Thursday it was not informed of any potential public tender offer for its shares, which opened 17 percent higher after Bloomberg reported that General Electric was in talks to buy the French turbine and train maker for about $13 billion.

  • Hedge fund & big pharma pair up     Wednesday, 23 Apr 2014 | 1:32 PM ET

    CNBC's Dominic Chu provides a timeline of Bill Ackman's stake in Allergan.

  • Carl Icahn's take on Ackman & Valeant     Wednesday, 23 Apr 2014 | 9:19 AM ET

    Activist investor Carl Icahn comments on Bill Ackman's role in the Valeant Pharmaceuticals bid for Allergan. The "Squawk on the Street" team provide insight.

  • Cramer: Can't lose if you're Ackman     Wednesday, 23 Apr 2014 | 9:17 AM ET

    The "Squawk on the Street" news team discuss the involvement of Bill Ackman in the deal between Valeant Pharmaceuticals and Allergan.

  • William Ackman, Pershing Square Capital Management, explains how his partnership with Valeant is structured. And J. Michael Pearson, Valeant chairman & CEO, discusses why he partnered with Ackman instead of pursing Allergan alone. Creating shareholder value is our job, says Pearson.

  • Ackman: Allergan clear fit for Valeant     Wednesday, 23 Apr 2014 | 7:41 AM ET

    William Ackman, Pershing Square Capital Management, explains why he is helping Valeant buy Allergan.

  • J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, weighs in on news that Allergan has adopted a "poison pill" defense strategy. Also Pearson shares his thoughts on adding some of Allergan's notable cosmetic products like Botox and Restasis to its growing arsenal.

  • Valeant CEO: Allergan has a great set of assets     Wednesday, 23 Apr 2014 | 7:33 AM ET

    J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, explains why he decided to pursue Allergan and shares his R&D business model, with CNBC's Kate Kelly. This year we are launching 19 products in the United States, says Pearson.

  • Ackman: Valeant fit into Pershing investing mold     Wednesday, 23 Apr 2014 | 7:32 AM ET

    William Ackman, Pershing Square Capital Management, explains why he decided to team up with Valeant Pharmaceuticals to make a play for Allergan.

  • Einhorn's new course     Tuesday, 22 Apr 2014 | 2:31 PM ET

    Sandy Villere, Villere Funds, shares his thoughts on Greenlight Capital's new stake in Conn's.

  • Pharma deal frenzy     Tuesday, 22 Apr 2014 | 10:01 AM ET

    CNBC's Meg Tirrell digs into the friendly and hostile M&A action taking place in pharmaceuticals, including a deal between Novartis and GlaxoSmithKline, and Valeant Pharmaceuticals bid for Allergan.

  • Valeant's offer for Allergan     Tuesday, 22 Apr 2014 | 8:03 AM ET

    Valeant Pharmaceuticals offered $48.30 share cash, as well as 0.83 shares for Allergan. CNBC's Meg Tirrell provides insight.